Oxford, UK – 6 May 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:Oxford Biomedica), a leading gene and cell therapy company, today announces that new data has been presented from two clinical studies indicating ground-breaking long-term four-year sustained and, in one of the studies, dose-dependent gene expression with the Company’s LentiVector® delivery platform.
On 5 May 2016, Professor Stéphane Palfi presented a poster on Oxford Biomedica-101, a gene therapy product for the treatment of Parkinson’s disease (PD), at the 19th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington DC, USA. In the Phase I/II study 15 advanced PD patients were treated with Oxford Biomedica-101 in three dose cohorts. Oxford Biomedica-101 demonstrated a favourable safety profile and a statistically significant improvement in motor function relative to baseline at six and 12 months post-treatment. The most recent follow-up data, presented this week, shows that the majority of patients continue to experience improvement in motor function relative to baseline over the four years since treatment. The Company has since developed Oxford Biomedica-102, a more potent version of Oxford Biomedica-101, and is planning to start a Phase I/II study in mid-2016. Oxford Biomedica-102 is Oxford BioMedica’s gene therapy product that utilises its proprietary LentiVector® delivery platform to transfer three genes for dopamine synthesis in the striatum.
In addition, on 4 May 2016, Dr Andreas Lauer gave an oral presentation on Oxford BioMedica’s LentiVector®-based treatment for neovascular age-related macular degeneration (wet AMD), at the Association for Research in Vision and Ophthalmology (ARVO) conference in Seattle, USA. Consistent with results previously announced at the ARVO conference, the new data presented demonstrates that LentiVector® gene expression was dose-dependent and continued without significant decline for more than four years.
Commenting on the new emerging data, John Dawson, Chief Executive Officer of Oxford BioMedica, said: “We are very encouraged by the demonstration of long term expression and clinical benefit in patients indicated by the four-year follow-up data from these two clinical studies. We believe this is the first time gene therapy products have been directly measured in the eye and the longevity in both expression and efficacy to date reinforces the benefits of the Company’s pioneering LentiVector® gene delivery platform in the treatment of chronic conditions.”
-Ends-